rheumatology
Medicines

Denosumab PI updated to reflect potential cardiac risk

Product Information for the fully human monoclonal antibody denosumab have been updated regarding the potential risk of QT interval prolongation associated with hypocalcaemia. Hypocalcaemia is a known effect of denosumab and was already captured in the PI, the TGA said in its latest Medicines Safety Update.  The potential risk of QT interval prolongation was identified ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic